Researchers sought to determine if momelotinib provided better improvements in anemia in patients with myelofibrosis, compared with treatment with danazol.
Researchers sought to verify the association of mutations in the splicing pathway gene SF3B1 with low bone marrow blast counts and increased ring sideroblasts in MDS.